Abstract:Abstract Background Major depressive disorder (MDD), also known as depression, has become the most prevalent mood disorder today. Currently, the diagnosis remains a major challenge given the disease heterogeneity and have been made by associating signs and symptoms with other diagnostic criteria. Several treatment options are available for MDD. However, less than 35% of patients achieve remission while 60% may show some degree of resistance to treatment even when receiving antidepressant treatment according to consensus guidelines and using measurement-based care. Between difficulties associated with the management of MDD, the lack of consensus on classification, diagnosis, and treatment stands out. Because of the incomplete understanding of MDD pathogenesis, it is urgent to develop studies that can help in the elucidation of the mechanisms related to the disease and the identification of biomarkers that allow its correct classification. Thus, this work aimed to perform a meta-analysis study to identify potential molecular biomarkers from different NGS databases. Methods Datasets from seven association studies stored in the IEU Open GWAS Project Database were selected. The meta-analysis was performed using the METAL tool (https://genome.sph.umich.edu/wiki/METAL_Documentation), which combines the relevance of the p-values, sample size, and the direction of the effect size. The criteria adopted for selecting the datasets were: (1) Specification of “depression”, “major depressive disorder” or “major depression” as the only phenotype; and (2) description of allele frequency data. The threshold for results significance was defined as P-value ≤5 × 10−8. After performing the analyses, only the SNPs whose direction of effect was the same in all original studies were evaluated, considering only the set of SNPs that were not significant in the original studies. Results After performing the meta-analysis, 348 new SNPs with P-value ≤5 × 10−8 were identified and, of those, 133 SNPs were mapped next to 17 genes. None of these genes was previously associated with depression. However, the GABBR1 gene, which encodes a type B GABA receptor subunit, has been associated with alcoholism, while the SORCS3 gene has been associated with attention deficit/hyperactivity disorder and Alzheimer’s disease. Conclusions The meta-analysis findings could help elucidate genes and polymorphisms involved in MDD pathogenesis. Due to MDD heterogeneity is nearly impossible to restrict and select a single disease biomarker. It is worth noting that only the identification of genetic polymorphisms involved in MDD development cannot be the only source of potential biomarkers for MDD. Indeed, it is necessary to extend the analysis to other components, such as regulatory regions, epigenetics, metabolites, etc. However, this work provide new insights into the identification of MDD potential biomarkers that can be better investigated in association to others factors related to the disease.

Understanding ayahuasca effects in major depressive disorder treatment through in vitro metabolomics and bioinformatics

Effect Of Ayahuasca on Experimental Models of Ethanol Addiction and Immunohistochemistry Analysis in Rodents

Differentiation of Ayahuasca Samples According to Preparation Mode and Botanical Varieties Using Metabolomics

Gut Microbiota Metabolites in Major Depressive Disorder—Deep Insights into Their Pathophysiological Role and Potential Translational Applications

Plasma Metabolomics Profiling of Metabolic Pathways Affected by Major Depressive Disorder

Ayahuasca: Pharmacology, neuroscience and therapeutic potential

Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges

Effects of pharmacological treatment on metabolomic alterations in animal models of depression

Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use: A Single-blind, Feasibility, Proof-of-Concept Trial

N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine

The contribution of polyamine pathway to determinations of diagnosis for treatment-resistant depression: A metabolomic analysis

Based on UPLC-Q-TOF-MS/MS, Systematic Network Pharmacology, and Molecular Docking to Explore the Potential Mechanism of Fructus Aurantii for Major Depression Disorder

Interplay of Metabolome and Gut Microbiome in Individuals With Major Depressive Disorder vs Control Individuals.

Emerging Application of Metabolomics on Chinese Herbal Medicine for Depressive Disorder.

Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research

The Effects of Ayahuasca on Psychological Disorders: A Systematic Literature Review

Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder

Ceremonial Ayahuasca in Amazonian Retreats-Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder

B-264 Identification of Potential Biomarkers Related to Major Depressive Disorder Using a Meta-Analysis Approach

Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes